Ignite Creation Date:
2025-12-25 @ 2:23 AM
Ignite Modification Date:
2025-12-28 @ 12:07 AM
Study NCT ID:
NCT00944034
Status:
COMPLETED
Last Update Posted:
2017-08-14
First Post:
2009-07-21
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12
Sponsor:
Novartis Vaccines
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-07
Start Date Type:
None
Primary Completion Date:
2011-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-01
Completion Date Type:
ACTUAL
First Submit Date:
2009-07-21
First Submit QC Date:
None
Study First Post Date:
2009-07-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2015-02-16
Results First Submit QC Date:
None
Results First Post Date:
2015-11-10
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-07-12
Last Update Post Date:
2017-08-14
Last Update Post Date Type:
ACTUAL